Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma.
checkpoint molecules
classical hodgkin lymphoma
multiplex immunohistochemistry
survival
tumor microenvironment
tumor-associated macrophages
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 Apr 2020
04 Apr 2020
Historique:
received:
04
03
2020
revised:
25
03
2020
accepted:
30
03
2020
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
9
4
2020
Statut:
epublish
Résumé
Tumor microenvironment and immune escape affect pathogenesis and survival in classical Hodgkin lymphoma (cHL). While tumor-associated macrophage (TAM) content has been associated with poor outcomes, macrophage-derived determinants with clinical impact have remained undefined. Here, we have used multiplex immunohistochemistry and digital image analysis to characterize TAM immunophenotypes with regard to expression of checkpoint molecules programmed cell death ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase 1 (IDO-1) from the diagnostic tumor tissue samples of 130 cHL patients, and correlated the findings with clinical characteristics and survival. We show that a large proportion of TAMs express PD-L1 (CD68
Identifiants
pubmed: 32260340
pii: cancers12040877
doi: 10.3390/cancers12040877
pmc: PMC7225916
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Academy of Finland
ID : 311171
Organisme : Sigrid Juséliuksen Säätiö
ID : NA
Organisme : Finnish Cancer Organizations
ID : NA
Organisme : Helsingin Yliopisto
ID : NA
Organisme : Helsingin ja Uudenmaan Sairaanhoitopiiri
ID : TYH2015401
Organisme : Orionin Tutkimussäätiö
ID : NA
Organisme : Finnish Society for Oncology
ID : NA
Références
Blood. 2017 Nov 30;130(22):2420-2430
pubmed: 28893733
Ann Oncol. 2012 Mar;23(3):736-42
pubmed: 21602260
Haematologica. 2012 Jul;97(7):1080-4
pubmed: 22315492
Cancers (Basel). 2018 Jun 15;10(6):
pubmed: 29914088
Blood. 2012 Oct 18;120(16):3280-7
pubmed: 22948049
Hematol Oncol. 2017 Mar;35(1):69-78
pubmed: 26251194
Cancer Immunol Immunother. 2014 Jul;63(7):721-35
pubmed: 24711084
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):144-50
pubmed: 25696847
BMC Med. 2016 Oct 17;14(1):159
pubmed: 27745550
J Clin Oncol. 2016 Aug 10;34(23):2690-7
pubmed: 27069084
BMC Cancer. 2014 May 15;14:335
pubmed: 24886161
Ther Adv Hematol. 2017 May;8(5):175-180
pubmed: 28473905
Blood. 2009 Mar 19;113(12):2765-3775
pubmed: 19096012
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):310-316
pubmed: 29222272
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Lancet Oncol. 2016 Sep;17(9):1283-94
pubmed: 27451390
Clin Immunol. 2014 Jul;153(1):145-52
pubmed: 24780173
Hematol Oncol. 2017 Sep;35(3):296-302
pubmed: 27060262
Haematologica. 2019 Feb;104(2):338-346
pubmed: 30237271
Int Immunopharmacol. 2017 Jun;47:70-77
pubmed: 28365507
Blood. 2018 Apr 19;131(16):1809-1819
pubmed: 29449276
PLoS One. 2014 Jan 29;9(1):e87066
pubmed: 24489836
Haematologica. 2016 Jul;101(7):794-802
pubmed: 27365459
Haematologica. 2018 Nov;103(11):1908-1914
pubmed: 30026337
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
Blood Adv. 2017 Aug 08;1(18):1427-1439
pubmed: 29296784
Front Oncol. 2018 Oct 04;8:423
pubmed: 30338242
Leuk Lymphoma. 2014 May;55(5):1031-7
pubmed: 24067108
Cancer Lett. 2016 Sep 28;380(1):243-52
pubmed: 26474544
Oncol Res Treat. 2017;40(11):654-660
pubmed: 29065424
Cancer Res. 2019 Apr 1;79(7):1493-1506
pubmed: 30679180
Tumour Biol. 2016 Jun;37(6):7507-14
pubmed: 26678894
Haematologica. 2011 Feb;96(2):269-76
pubmed: 21071500
J Clin Oncol. 2016 Nov 1;34(31):3733-3739
pubmed: 27354476
N Engl J Med. 2010 Mar 11;362(10):875-85
pubmed: 20220182
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
J Clin Oncol. 2011 May 10;29(14):1812-26
pubmed: 21483001
Genome Biol. 2006;7(10):R100
pubmed: 17076895